A Novel Lpxc Inhibitor With Pan-Resistant Pseudomonas and Burkholderia Activity
Contract Overview
Contract Amount: $27,840,245 ($27.8M)
Contractor: Revagenix Inc
Awarding Agency: Department of Health and Human Services
Start Date: 2022-09-22
End Date: 2028-04-25
Contract Duration: 2,042 days
Daily Burn Rate: $13.6K/day
Official Description: A NOVEL LPXC INHIBITOR WITH PAN-RESISTANT PSEUDOMONAS AND BURKHOLDERIA ACTIVITY.
Place of Performance
Location: California, 94401